The results presented should promote an update of the recommendations for pharmacological treatment of heart failure in mildly reduced and preserved EF to include the use of SGLT2 inhibitors in patients with HF across the full spectrum of ejection fraction, irrespective of diabetes status and care setting and regardless of background therapies51. The gene discussed is SLC5A2; the disease is heart failure.